Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial
- 18 August 2022
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (9) , 3833-3841
Abstract
Previous proton magnetic resonance spectroscopy (1H-MRS) studies suggest a perturbation in glutamate and/or GABA in Major Depressive Disorder (MDD). However, no studies examine the ratio of glutamate and glutamine (Glx) to GABA (Glx/GABA) as it relates to depressive symptoms, which may be more sensitive than either single metabolite. Using a within-subject design, we hypothesized that reduction in depressive symptoms correlates with reduction in Glx/GABA in the anterior cingulate cortex (ACC). The present trial is a randomized clinical trial that utilized 1H-MRS to examine Glx/GABA before and after 8 weeks of escitalopram or placebo. Participants completed the 17-item Hamilton Depression Rating Scale (HDRS17) and underwent magnetic resonance spectroscopy before and after treatment. Two GABA-edited MEGA-PRESS acquisitions were interleaved with a water unsuppressed reference scan. GABA and Glx were quantified from the average difference spectrum, with preprocessing using Gannet and spectral fitting using TARQUIN. Linear mixed models were utilized to evaluate relationships between change in HDRS17 and change in Glx/GABA using a univariate linear regression model, multiple linear regression incorporating treatment type as a covariate, and Bayes Factor (BF) hypothesis testing to examine strength of evidence. No significant relationship was detected between percent change in Glx, GABA, or Glx/GABA and percent change in HDRS17, regardless of treatment type. Further, MDD severity before/after treatment did not correlate with ACC Glx/GABA. In light of variable findings in the literature and lack of association in our investigation, future directions should include evaluating glutamate and glutamine individually to shed light on the underpinnings of MDD severity. Advancing Personalized Antidepressant Treatment Using PET/MRI, ClinicalTrials.gov, NCT02623205.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH104512)
- Brain and Behavior Research Foundation
- Dana Foundation
- New York State Faculty Development Grant
This publication has 67 references indexed in Scilit:
- Region-specific glutamate changes in patients with unipolar depressionJournal of Psychiatric Research, 2012
- Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartateInternational Journal of Neuropsychopharmacology, 2012
- Region and state specific glutamate downregulation in major depressive disorder: A meta-analysis of 1H-MRS findingsNeuroscience & Biobehavioral Reviews, 2012
- Towards a glutamate hypothesis of depressionNeuropharmacology, 2012
- The role of glutamate on the action of antidepressantsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Elevated cortical glutamate in young people at increased familial risk of depressionInternational Journal of Neuropsychopharmacology, 2011
- Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood DisordersBiological Psychiatry, 2010
- Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insulaFrontiers in Systems Neuroscience, 2010
- Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive DisorderBiological Psychiatry, 2009
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979